secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0000950170-24-035613
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta shares NKX019 B-cell reconstitution and PK data from Phase 1 NHL trial
-----------------------------------------------------------------------------

- After NKX019 treatment, circulating CD19+ cells rapidly depleted; B-cell repertoire recovered with naïve, non-class-switched isotypes in 5 patients at 3 months.
- No patients had prior CAR T therapy; recovery pattern consistent with CAR T experience in autoimmune disease.
- Preliminary PK data from 2 patients with DLBCL show similar NKX019 exposure after Flu/Cy vs Cy alone lymphodepletion.
- B-cell recovery confirmed by single-cell RNA profiling, showing naïve and intermediate B cell transcriptome profiles.
- Company highlights potential of NKX019 for autoimmune diseases such as lupus nephritis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024035613/0000950170-24-035613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024035613/nktx-20240325.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-035613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer